| Literature DB >> 34145494 |
Peter P Grimminger1, Julia I Staubitz2, Daniel Perez3, Tarik Ghadban3, Matthias Reeh3, Pasquale Scognamiglio3, Jakob R Izbicki3, Matthias Biebl4, Hans Fuchs5, Christiane J Bruns5, Hauke Lang2, Thomas Becker6, Jan-Hendrik Egberts6.
Abstract
BACKGROUND: Oncological esophageal surgery has evolved significantly in the last decades. From open esophagectomy over (hybrid) minimally invasive surgery, nowadays, robot-assisted minimally invasive esophagectomy (RAMIE) approaches are applied. Current techniques require an analysis of possible advantages and disadvantages indicating the direction towards a novel gold standard.Entities:
Keywords: Da Vinci Xi; Esophagectomy; Ivor Lewis; RAMIE; Robotic technique
Mesh:
Year: 2021 PMID: 34145494 PMCID: PMC8523396 DOI: 10.1007/s11605-021-05044-8
Source DB: PubMed Journal: J Gastrointest Surg ISSN: 1091-255X Impact factor: 3.452
Basic data for totally robotic (T-RAMIE) and hybrid robotic (H-RAMIE) approaches
| Total | T-RAMIE | H-RAMIE | p-value | |
|---|---|---|---|---|
| Age in years (median, range) | 62 (22–86) | 61 (22–86) | 64 (46–79) | 0.337 c |
| Sex | 0.340 c | |||
| Male (N, %a) | 201, 83.1 | 148, 84.6 | 53, 79.1 | |
| Female (N, %a) | 41, 16.9 | 27, 15.4 | 14, 20.9 | |
| BMI (median, range) | 26, 16–46 | 25, 16–46 | 25, 16–41 | 0.310 c |
| Comorbidity (N, %a) | 172, 71.1 | 120, 68.6 | 52, 77.6 | 0.205 d |
| Diabetes (N, %a) | 27, 11.2 | 22, 12.6 | 5, 7.5 | 0.362 d |
| Pulmonary comorbidity (N, %a) | 38, 15.7 | 25, 14.3 | 13, 19.4 | 0.329 d |
| Cardiac comorbidity (N, %a) | 75, 31 | 41, 23.4 | 34, 50.7 | |
| Vascular comorbidity (N, %a) | 50, 20.7 | 48, 27.4 | 2, 3.0 | |
| Oncologic comorbidity (N, %a) | 8, 3.3 | 8, 4.6 | 0, 0 | 0.111 d |
| Neurologic comorbidity (N, %a) | 12, 5.5 | 10, 5.7 | 2, 3.0 | 0.519 d |
| No comorbidity (N, %a) | 70, 28.9 | 55, 31.4 | 15, 22.4 | 0.205 d |
| Entity | 0.245 e | |||
| Adenocarcinoma (N, %a) | 199, 82.2 | 142, 81.1 | 57, 85.1 | |
| Squamous cell carcinoma (N, %a) | 35, 14.5 | 27, 15.4 | 8, 11.9 | |
| Other (N, %a) | 8, 3.3 | 6,3.5 | 2, 3.0 | |
| Neoadjuvant therapy | 0.336 e | |||
| Chemotherapy (N, %a) | 100, 41.3 | 76, 43.4 | 24, 35.8 | |
| Radiochemotherapy (N, %a) | 101, 41.7 | 68, 38.8 | 33, 49.3 | |
| Duration of surgery (median, range) | 396, 222–640 | 385, 222–640 | 427, 252–579 | |
| Length of hospital stay in days (median, range) | 13, 7–92 | 13, 7–92 | 16, 10–64 | 0.014 c |
| Conversion rate (N, %a) | 14, 5.8 | 5, 2.9 | 9, 13.4 | |
| R0 resection (N, %b) | 223, 93.3 | 163, 93.7 | 60, 92.3 | 0.772 d |
| N resected lymph nodes (median, range) | 28, 8 – 81 | 28, 8–81 | 29, 8–54 | 0.550 c |
| Histology benign | 3 | 1 | 2 | 0.186 d |
| Histology malignant | 239 | 174 | 65 | 0.186 d |
| T-Stage | 0.240 e | |||
| T0 (N) | 36 | 27 | 9 | |
| T1 (N) | 43 | 26 | 17 | |
| T2 (N) | 37 | 25 | 12 | |
| T3 (N) | 117 | 92 | 25 | |
| T4 (N) | 6 | 4 | 2 | |
| Benign (N) | 3 | 1 | 2 | |
| N-Stage | 0.273 e | |||
| N0 (N) | 121 | 83 | 38 | |
| N1 (N) | 44 | 31 | 13 | |
| N2 (N) | 44 | 35 | 9 | |
| N3 (N) | 30 | 25 | 5 | |
| Benign (N) | 3 | 1 | 2 | |
| Mortality (N, %a) | 2, 0.8 | 2, 1.1 | 0, 0 | 1.000 d |
| Overall morbidity (N, %a) | 88, 36.4 | 56, 32.0 | 32, 47.8 |
aReferred to number of operations per group (total, totally robotic, or hybrid robotic)
bReferred to number of malignant tumors per group
cMann-Whitney U test
dFisher’s exact test
eChi-squared test
Fig. 1Risk ratios for postoperative complications in relation to the type of approach: totally robotic (T-RAMIE) versus hybrid robotic (H-RAMIE) esophagectomy